If you’re on the East Coast, you might be lucky enough to see a United States Air Force rocket sail through the air tonight, between 8:00 and 10:00 P.M. EDT, carrying a tiny satellite into space. Weighing in at a meager 10 pounds, the “nanosatellite,” called PharmSat, was developed by NASA to study how yeast responds to antifungal drugs while in orbit.
Past studies have shown that microorganisms can grow more virulent in space, and another nanosatellite mission, GeneSat, launched in 2006 to test how E. coli bacteria behave in space. The goal of such research is to better understand the biological effects of space. (GeneSat was an $8 million project, and its design is the basis for PharmSat.)
The new nanosatellite contains a sensor-studded laboratory that will detect the growth, density, and health of yeast cells receiving three different doses of the antifungal drug over the course of 96 hours. Scientists on the ground will initiate the experiment one hour after liftoff, and data will be sent back to Earth in near real time for up to six months, assuming that no technical glitches or failures occur.
Good luck, PharmSat!
This startup wants to copy you into an embryo for organ harvesting
With plans to create realistic synthetic embryos, grown in jars, Renewal Bio is on a journey to the horizon of science and ethics.
VR is as good as psychedelics at helping people reach transcendence
On key metrics, a VR experience elicited a response indistinguishable from subjects who took medium doses of LSD or magic mushrooms.
This nanoparticle could be the key to a universal covid vaccine
Ending the covid pandemic might well require a vaccine that protects against any new strains. Researchers may have found a strategy that will work.
This artist is dominating AI-generated art. And he’s not happy about it.
Greg Rutkowski is a more popular prompt than Picasso.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.